| Formulary Chapter 3: Respiratory system - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
03.01 |
Bronchodilators
(0,4)
|
|
|
Asthma
(0,1)
|
|
|
Chronic obstructive pulmonary disease
(0,0)
|
|
|
Croup
(0,0)
|
|
03.01.01 |
Adrenoceptor agonists
(0,0)
|
|
03.01.01.01 |
Selective Beta2 agonists
(6,7)
|
|
|
Short-acting beta2 agonists
(0,0)
|
|
|
Long-acting beta2 agonists
(0,1)
|
|
03.01.01.02 |
Other adrenoceptor agonists
(1,1)
|
|
03.01.02 |
Antimuscarinic bronchodilators
(4,3)
|
|
|
Short Acting Anti-muscarinic Bronchodilators
(0,0)
|
|
|
Long Acting Anti-muscarinic Bronchodilators
(0,0)
|
|
03.01.03 |
Theophylline
(5,0)
|
|
03.01.04 |
Compound bronchodilator preparations
(4,3)
|
|
03.01.05 |
Peak flow meters, inhaler devices and nebulisers
(0,0)
|
|
|
Peak flow meters
(2,2)
|
|
|
Drug delivery devices
(2,1)
|
|
|
Nebulisers
(0,0)
|
|
|
Nebuliser Diluent
(1,0)
|
|
03.02 |
Corticosteroids
(21,19)
|
|
03.02.01 |
Inhaled Corticosteroids
(0,0)
|
|
03.02.02 |
Combination products (ICS+LABA) for asthma
(0,0)
|
|
|
Low dose
(0,0)
|
|
|
Moderate dose
(0,0)
|
|
|
High dose
(0,0)
|
|
03.02.03 |
Combination products (ICS+LABA) for COPD
(0,0)
|
|
|
Triple Therapy products for COPD
(6,0)
|
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists
(0,5)
|
|
03.03.01 |
Cromoglicate and related therapy
(0,0)
|
|
|
Related therapy
(0,0)
|
|
03.03.02 |
Leukotriene receptor antagonists
(1,1)
|
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies
(7,22)
|
|
03.04.01 |
Antihistamines
(0,0)
|
|
|
Non-sedating antihistamines
(4,4)
|
|
|
Sedating antihistamines
(4,0)
|
|
03.04.02 |
Allergen Immunotherapy
(4,0)
|
|
|
Omalizumab
(1,0)
|
|
03.04.03 |
Allergic emergencies
(0,0)
|
|
|
Anaphylaxis
(5,0)
|
|
|
Angioedema
(7,0)
|
|
|
Intramuscular adrenaline (epinephrine)
(0,0)
|
|
|
Intravenous adrenaline (epinephrine)
(0,0)
|
|
|
Self-administration of adrenaline (epinephrine)
(0,0)
|
|
03.05 |
Respiratory stimulants and pulmonary surfactants
(0,0)
|
|
03.05.01 |
Respiratory stimulants
(3,0)
|
|
03.05.02 |
Pulmonary surfactants
(1,1)
|
|
03.06 |
Oxygen
(1,0)
|
|
|
Long-term oxygen therapy
(1,0)
|
|
|
Short burst oxygen therpary
(0,0)
|
|
|
Ambulatory oxygen therapy
(0,0)
|
|
|
Oxygen therapy equipment
(0,0)
|
|
|
Arrangements for supplying oxygen
(0,0)
|
|
03.07 |
Mucolytics
(13,8)
|
|
|
Dornase alfa
(1,0)
|
|
|
Hypertonic Sodium Chloride
(2,2)
|
|
03.08 |
Aromatic inhalations
(0,2)
|
|
03.09 |
Cough preparations
(16,12)
|
|
03.09.01 |
Cough suppressants
(0,2)
|
|
|
Palliative care
(0,0)
|
|
03.09.02 |
Expectorant and demulcent cough preparations
(2,0)
|
|
03.10 |
Systemic nasal decongestants
(1,0)
|
|
03.11 |
Antifibrotics
(3,0)
|
|
03.12 |
Other drugs for Interstitial lung disease (idiopathic pulmonary fibrosis)
(3,0)
|
|
03.13 |
Nebulised antimicrobials for cystic fibrosis
(14,0)
|
|
03.14 |
Monoclonal Antibody
(5,0)
|
|
03.15 |
Cystic fibrosis
(0,0)
|
